Compare Ascendis Pharma A/S (ASND) vs Southwest Airlines Co (LUV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Southwest Airlines Co — how do they compare? Ascendis Pharma A/S trades at $252.27 (market cap $16.67B), while Southwest Airlines Co trades at $45.59 (market cap $22.27B). The key difference: Southwest Airlines Co is the larger of the two by market cap, and Southwest Airlines Co pays a 1.58% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | LUV | |
|---|---|---|
Market Cap | $16.67B | $22.27B |
Sector | Health | Industrials |
52-Week High | $277.18 | $54.80 |
52-Week Low | $189.74 | $29.67 |
Enterprise Value | $17.04B | $25.37B |
Dividend Yield | — | 1.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Southwest Airlines (LUV) trades at $44.9, down 4.57% on the day, with a bearish technical signal from moving averages. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1 2026, while revenue growth is projected to rise to $30.1B in 2026. Recent news highlights board appointments and initiatives to attract business travelers, amid a volatile fuel cost environment.
LUV presents a cautious opportunity with a consensus price target of $53.86 implying upside, supported by improving cash flow and dividend payments. Risks include fuel price volatility, execution on new business offerings, and competitive pressures, requiring careful monitoring of earnings consistency and cost management.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Southwest Airlines Co
Southwest Airlines is the largest domestic carrier in the United States, as measured by the number of originating passengers boarded. Southwest operates over 700 aircraft in an all-Boeing 737 fleet. Despite expanding into longer routes and business travel, the airline still specializes in short-haul leisure flights, using a point-to-point network. Southwest operates a low-cost carrier business model.
Read more on LUV →
